Comparative Benchmarking
In the context of the broader market, RADX competes directly with industry leaders such as SERA and NAKA. With a market capitalization of $52.16M, it holds a significant position in the sector. When comparing efficiency, RADX's gross margin of N/A stands against SERA's -200.00% and NAKA's 49.70%. Such benchmarking helps identify whether Radiopharm Theranostics Ltd is trading at a premium or discount relative to its financial performance.
